2026 ASCO | Innovent Presents Long-Term Follow-up Results from the PoC Study of IBI363 (TAK-928) (PD-1/IL-2α-bias bispecific fusion protein), Showing Robust Survival Benefits in Advanced Immunotherapy-Resistant Non-Small Cell Lung Cancer

After long-term follow-up, IBI363 monotherapy demonstrated strong overall survival (OS) with a…

New Taipei City Showcases Smart Manufacturing Strength at AUTOMATE 2026

Exploring New Business Opportunities with Global Buyers TAIPEI, June 1, 2026 /PRNewswire/…

AMD Bundles Carbice Ice Pad with Ryzen™ 7 5800X3D

The Carbice Ice Pad provides a reliable, peel-and-stick, maintenance-free thermal paste alternative designed…

Carbice and Noctua Partner to Bring Advanced Thermal Pad Technology to DIY PC Builders

Noctua is the exclusive retail distributor of Carbice® IP90 thermal pads for…

Lynk Pharmaceuticals Announces NMPA Approval of LNK01004 Ointment's Phase II Clinical Trial for the Treatment of Vitiligo and Chronic Hand Eczema

HANGZHOU, China, SHANGHAI and BOSTON, June 1, 2026 /PRNewswire/ — Lynk Pharmaceuticals…

United Imaging Spotlights Molecular Imaging Showstoppers at SNMMI 2026

LOS ANGELES, May 31, 2026 /PRNewswire/ — United Imaging, a global innovator…

BLUETTI Launches EOFY Sale on Power Solutions with Up to 44% OFF

SYDNEY, June 1, 2026 /PRNewswire/ — Clean energy leader BLUETTI is unleashing…

HARMONi-6 Demonstrates Significant Overall Survival Benefit (HR=0.66): Ivonescimab Plus Chemotherapy Superior to PD-1 Plus Chemotherapy in First-Line sq-NSCLC Landmark Results to Be Presented at ASCO 2026 Plenary Session

CHICAGO, May 31, 2026 /PRNewswire/ — Akeso, Inc. (9926.HK) ("Akeso" or the…